

Alloplex Leadership Team

Alloplex Biotherapeutics Inc is a privately owned Boston-based cellular therapeutics company founded in 2016. Its global headquarters and laboratory are located in Woburn MA, USA; its wholly owned subsidiary Alloplex Australia Pty Ltd is based in Adelaide, Australia. The company has 4 key officers: CEO, CSO, CDO and Acting CFO.

The company is led by a small and nimble senior management team bringing the advantage of long-term relationships and complementary skill sets to bear on a singular problem. These skillsets span immunology and analytical science, pharmaceutical development, clinical and regulatory expertise, and business development.

The Alloplex Senior Leadership Team



Frank Borriello, M.D., PhD.
Scientific Founder & Chief Executive Officer

Frank initial description: Frank Borriello, PhD, MD, leads Alloplex Biotherapeutics Inc., a company he established in 2016 based on an original, and now patented, concept.

Read More at: <https://alloplexbio.com/team-members/frank-borriello/>



James A. Lederer, PhD
Chief Scientific Officer

An expert in the injury induced modulation of the immune system and analytic methods for cell characterization, Dr. Lederer is an Associate Professor in the Department of Surgery, Brigham and Women's Hospital and Harvard Medical School and Director.

Read More at: <https://alloplexbio.com/team-members/james-lederer/>



Sharryn Gargosky, PhD
Chief Development Officer

A clinical, scientific, and regulatory professional with over 25 years of experience in global clinical development and operations in the field of pharmaceutical and biologic development. Having managed international programs from early research phase through the U.S. Food & Drug Administration approval process. Originally from Australia, Dr. Gargosky leads our clinical development efforts.

Read More at: <https://alloplexbio.com/team-members/sharron-gargosky/>

The Alloplex Corporate Board



Dr. Sung-wuk Kim Corporate Board member

Dr. Sung-wuk Kim is an entrepreneur, angel investor and accomplished inventor who has made significant contributions to advance drug development: receiving more than 30 patents in a broad range of areas which include formulation, biologics and small molecule drugs.

Read More at: <https://alloplexbio.com/team-members/dr-sung-wuk-kim/>



Paul Sowyrda Corporate Board member

Paul Sowyrda is an accomplished executive and inventor with over 30 years of experience in the pharmaceutical and biotechnology sectors. He co-founded Novellus, Inc. and served as its Executive Vice President until its acquisition by Brooklyn ImmunoTherapeutics in 2021. Paul has held key leadership roles, including Vice President of Drug Development at CIBA, Vice President of Development and Marketing at Dusa Pharmaceuticals, and Vice President of Product Development for Chiron Corporation.

Read More at: <https://alloplexbio.com/team-members/paul-sowyrda>